萬里揚(002434.SZ):擬1.1億元收購萬里揚能源公司51%股份
格隆匯1月6日丨萬里揚(002434.SZ)公佈,2022年1月6日,公司與萬里揚集團、吳月華、陳瑋琪、徐一夫、周才良、張妍、吳南、劉漠塵簽署了《關於浙江萬里揚能源科技股份有限公司的股權轉讓協議》。
公司以1.10億元的價格收購萬里揚集團、吳月華、陳瑋琪、徐一夫、周才良、張妍、吳南、劉漠塵合計持有的浙江萬里揚能源科技股份有限公司(簡稱“萬里揚能源公司”)51%的股份(出資額為1.02億元,該出資已由原股東實繳到位,原股東剩餘49%的出資額尚未實繳到位,將於2022年12月31日前實繳到位)。此次股權收購事項構成關聯交易。
股權轉讓完成後,萬里揚能源公司成為公司的控股子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.